arrow
M

Massimo Iavarone

Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico
H指数:45
被引数:7,736

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Stratifying Cardiovascular Risk in Patients With HCC Receiving Atezolizumab/Bevacizumab: A Comparison of ESC and CARDIOSOR Scores

在采用阿替利珠单抗/贝伐珠单抗治疗的肝癌患者中分层心血管风险:ESC评分与CARDIOSOR评分的比较

2026-10-070
OAAI
Early hepatic decompensation is associated with mortality in patients with HCC treated with atezolizumab plus bevacizumab or durvalumab plus tremelimumab

早期肝功能失代偿与接受阿替利珠单抗联合贝伐珠单抗或度伐利尤单抗联合特瑞普利单抗治疗的HCC患者死亡率相关

2026-09-070
PRE
Durvalumab–Tremelimumab in Advanced Hepatocellular Carcinoma: Real-World Data From the LOR-HCC (Lombardy Real-World HCC Group)

度伐鲁单抗–曲美木单抗在晚期肝细胞癌中的应用:来自LOR-HCC(伦巴第真实世界HCC研究组)的真实世界数据

2026-04-160
OAAI
Impact of Hepatocellular Carcinoma on the risk of liver decompensation: a comparative analysis of patients with and without HCC

肝细胞癌对肝功能失代偿风险的影响:有和无HCC患者的比较分析

2026-04-040
OAAI
Modified Charlson Comorbidity Index to Improve Management of Patients with Hepatocellular Carcinoma: A Step Towards Multiparametric Approach

改良版Charlson合并症指数在改善肝细胞癌患者管理中的应用:迈向多参数化方法的一步

Cancers
IF4.4
2026-04-030
OAAI
ASAP score predicts early HCC recurrence after complete radiological response to locoregional treatments

ASAP评分可预测局部区域治疗后完全放射学缓解后的早期HCC复发

2026-01-030
PREAI
The Effect of Metformin on Atezolizumab/Bevacizumab Treatment in Patients with Carcinoma and Diabetes

二甲双胍对接受阿替利珠单抗/贝伐珠单抗治疗的癌病患者的影响

2026-01-010
PRE
Reproducible safety and efficacy of durvalumab with or without tremelimumab for hepatocellular carcinoma in clinical practice: results of the DT-real study

在临床实践中,durvalumab联合或单药使用tremelimumab治疗肝细胞癌的可重复安全性及有效性:DT-real研究结果

2025-11-200
OAAI
Comparable 5-Year Survival in People With and Without HIV Following Hepatocellular Carcinoma Diagnosis: A Multicenter Study

HIV感染者与非感染者肝细胞癌诊断后的5年生存率比较:一项多中心研究

2025-11-181
OAAI
Hepatitis C Eradication Improves Oncologic and Clinical Outcomes in Patients Treated With Atezolizumab Plus Bevacizumab

丙型肝炎清除可改善接受阿替利珠单抗联合贝伐珠单抗治疗患者的肿瘤学和临床结局

2025-09-220
PREAI
Vessels That Encapsulate Tumor Cluster plus Unresectable Hepatocellular Carcinomas Benefit of Antiangiogenic Therapy

包裹肿瘤簇且无法切除的肝细胞癌血管的抗血管生成治疗获益

2025-09-010
OA
Breaking Barriers for Intensive Care Admission in Patients With Advanced HCC on Immunotherapy

突破接受免疫治疗晚期HCC患者进入重症监护的障碍

2025-08-120
OAAI
The impact of BCLC recommendations on survival for patients with hepatocellular carcinoma

Massimo, I.; Eleonora, A.; Lorenzo, C.; Mariangela, B.; Barbara, A.; Maria, I.A.; Angelo, S.; Giuseppe, C.; Annalisa, D.S.; Lucio, C.; et al. BCLC建议对肝细胞癌患者生存期的影响。Hepatol. Commun. 2025, 9, e0750. [Google Scholar] [CrossRef]

2025-07-140
OA
Early CTLA4 increase in CD45+blood cells: an emerging biomarker of atezolizumab-bevacizumab resistance and worse survival in advanced hepatocarcinoma

CD45+血液细胞中早期CTLA4增加:作为阿替利珠单抗-贝伐珠单抗耐药性及晚期肝细胞癌不良预后的新兴生物标志物

2025-03-010
OAAI
Atezolizumab plus bevacizumab as first-line treatment of unresectable hepatocellular carcinoma: interim analysis results from the phase IIIb AMETHISTA trial
2025-02-010
PRE
The changing epidemiology of patients with HCC receiving a first-line systemic therapy: insights from ARPES and ARTE databases (2008-2024)
2025-02-010
PRE